TFA Therapeutics (RAJAF) Payables (2020 - 2025)

TFA Therapeutics has reported Payables for 6 years, with the latest figure at $4.4 million in Q4 2025.

• On a quarterly basis, Payables rose 4.93% year-over-year to $4.4 million in Q4 2025; TTM through Dec 2025 was $4.4 million, a 4.93% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, up 4.93% from the prior year.
• Payables was $4.4 million for Q4 2025 at TFA Therapeutics, up from $4.2 million in the prior quarter.
• The five-year high for Payables was $4.4 million in Q4 2025, with the low at $62754.0 in Q4 2022.
• Average Payables over 5 years is $2.4 million, with a median of $2.2 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Payables plunged 96.27% in 2022, then surged 4347.57% in 2023.
• Over 5 years, Payables stood at $1.7 million in 2021, then slumped by 96.27% to $62754.0 in 2022, then soared by 4347.57% to $2.8 million in 2023, then jumped by 49.41% to $4.2 million in 2024, then grew by 4.93% to $4.4 million in 2025.
• The last three Payables figures came in at $4.4 million (Q4 2025), $4.2 million (Q4 2024), and $2.8 million (Q4 2023), per Business Quant data.